Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$2.16 USD
-0.06 (-2.70%)
Updated Jun 14, 2024 10:16 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 161 - 180 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1522 Discontinuation Longtime Coming; Encouraging Preliminary Activity With XMT-1536; Target Revised to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Addition of Dr. Huebner Rounds up the C-Suite
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18; Progress Toward Cohort Expansions for XMT-1536 and XMT-1522 in 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Corporate Update; Work in Progress With Clinical Clarity During 1H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Partial Clinical Hold Lifted, but Changes in Dosing May Extend Development Time
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Partial Clinical Hold in the Rearview, But a Step Back in Development Speed Is Warranted; PT Increased to $23 From $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
A Show Me Story With a Potential Near-Term Resolution of the Partial Clinical Hold
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
HEALTHCARE - 2018 Wedbush PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Timelines for Lifting of XMT1522 Hold and XMT1536 Data become Clearer
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Fork in the Road Moment Early in Drug Development; Target Lowered to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Clinical Hold Should Be a Temporary and Manageable Setback
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Uncertainty No Friend of the Stock, Expecting XMT-1522 to Clear Cohort 7 Over the Near Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
ASCO Abstract: Signs of Activity at Lower Doses; No DLT; and Clean Safety Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
No DLT Is Good DLT; Both High DAR Constructs Humming Along
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.